Technology | March 03, 2011

FDA Clears PET Imaging Reconstruction Application

March 3, 2011 – The U.S. Food and Drug Administration (FDA) has cleared a whole-body positron emission tomography (PET) application. Xpress.PET, by UltraSpect, enables reduced dose and acquisition time without compromising image quality.

The benefits of application, which is based on the company’s Wide-Beam Reconstruction (WBR) technology in whole body PET/CT scanning include:

• Reduced PET acquisition time to 15 minutes for a whole body Fludeoxyglucose (FDG) PET/CT scan

• Reduced injection dose, minimizing patient radiation exposure

• Improved image signal to noise ratio

• Enhanced patient throughput and department productivity

• Greater patient tolerance and comfort during scanning

“With new Xpress.PET users can shorten scan times or reduce FDG dose up to 40 percent--reducing a typical PET scan to 15 minutes for most patients instead of 24 minutes,” said Mack Burris, R.T., clinical product specialist for UltraSpect. “Alternatively, an FDG dose of a normal patient can be reduced to 10 mCi from 15 mCi. The initial product will be released for the GE Discovery LS PET/CT system and will be adapted to other PET/CT devices shortly, and will make the performance of older PET/CT scanners comparable to newer models.”

WBR products accurately compensate for the physical effects in data acquisition, such as resolution, attenuation and scatter, while controlling the noise level. Physicians have the same clinical information as typical PET/CT technology in shorter time periods or with lower injection dose, minimizing radiation exposure to patients and staff, while enhancing efficiency and patient throughput.

For more information: www.ultraspect.com

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Overlay Init